ZOLL Medical Receives 2009 North American Healthcare Innovation Award from Frost & Sullivan

Zoll Medical Corporation (NasdaqGS: ZOLL), a manufacturer of medical devices and related software solutions, announced today that it has received Frost & Sullivan’s 2009 North American Healthcare Innovation Award. ZOLL was recognized by Frost & Sullivan as a global leader in defibrillation and resuscitation for its solutions that have revolutionized critical care and advanced the practice of resuscitation through pacing, defibrillation, circulation, data management, and fluid resuscitation.

"ZOLL is driving innovation to accelerate a new level of care in the diagnosis, treatment and management of cardiac arrest, which results in better clinical outcomes and quality of life for patients,” said Gary Burk, Frost & Sullivan analyst. "Being acutely aware of the critical care space and overall healthcare trends, ZOLL has continuously delivered integrated solutions that encompass all facets of lifesaving resuscitation.”

"ZOLL’s integrated critical care product portfolio provides cutting-edge solutions that meet the growing demands of the ever-changing market landscape to assist first responders, healthcare professionals, government entities, military, and lay rescuers,” said Burk.

"This Frost & Sullivan Award reinforces our vision of improving the outcomes from sudden cardiac arrest, the leading cause of unexpected death worldwide,” said Jonathan A. Rennert, President of ZOLL. "Our key strength has been our continued focus on advancing resuscitation technology, and we’ve made significant strides with such industry breakthroughs as Real CPR Help^® and See-Thru CPR^®. We’ve also broadened our reach into data management and beyond resuscitation into temperature management for future growth for improving patient care.”

For the Healthcare Innovation Award, the following criteria were used to benchmark ZOLL Medical’s performance against key competitors:

• Breakthrough approach / degree of differentiation innovation compared to other market participants
• Product innovation in terms of unique or revolutionary technology
• Penetration rate of new markets
• Significance of innovation in the industry
• Leading proactive initiatives to improve value to customers
• Advancement of the industry through research
• Implementation of a new or unique pricing strategy
• Implementation of a new or unique marketing strategy
• Creating new venues, such as online services, for an established product

Highlights of ZOLL’s Portfolio for Strengthening Resuscitation Care

All of ZOLL’s AEDs and defibrillators include Real CPR Help^®, real-time CPR feedback to give rescuers to the proper rate and depth of chest compressions. The R Series^®, E Series^®, and AED Pro^® offer See-Thru CPR^®, industry-unique filtering technology that allows professional rescuers to view a patient’s underlying cardiac rhythm, by filtering CPR artifact during resuscitation efforts. ZOLL’s AutoPulse^® is a revolutionary non-invasive cardiac support pump that moves more blood more consistently than possible with manual chest compressions. The LifeVest^® Wearable Defibrillator is the world's first and only wearable automatic defibrillator and has a 98% first shock success rate. Most recently, ZOLL has expanded its critical care portfolio to include Intravascular Temperature Management Systems, which provide precise and rapid control of a patient's core temperature for both cooling and warming applications.

This integrated critical care portfolio includes:

• AED Plus^® Automated External Defibrillator
• AED Pro^®Automated External Defibrillator
• R Series^® Defibrillators
• AutoPulse^® Non-Invasive Cardiac Support Pump
• CodeNet^® Resuscitation Data Management System
• Defibrillator Electrodes
• LifeVest^® Wearable Defibrillator
• PocketCPR^® Personal CPR Coaching Device
• Intravascular Temperature Management (IVTM^™)
• SurePower^™ Defibrillator Battery System
• M Series^® CCT Defibrillator

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best in class positions in growth, innovation and leadership. The Company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best practice models to drive the generation, evaluation and implementation of powerful growth strategies. Frost & Sullivan leverages almost 50 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from 31 offices on six continents. To join our Growth Partnership, please visit www.frost.com.

About ZOLL Medical Corporation

ZOLL Medical Corporation develops and markets medical devices and software solutions that help advance emergency care and save lives, while increasing clinical and operational efficiencies. With products for defibrillation and monitoring, circulation and CPR feedback, data management, fluid resuscitation, and therapeutic temperature management, ZOLL provides a comprehensive set of technologies which help clinicians, EMS and fire professionals, and lay rescuers treat victims needing resuscitation and critical care.

A NASDAQ Global Select company and a Forbes 100 Most Trustworthy Company for the past three years, ZOLL develops and manufactures its products in the United States, in California, Colorado, Illinois, Massachusetts, Pennsylvania, and Rhode Island. More than 400 direct sales and service representatives, 1,100 business partners, and 200 independent representatives serve our customers in over 140 countries around the globe. For more information, visit www.zoll.com.

Certain statements contained in this press release, including statements regarding the future business of the Company, and other statements contained herein regarding matters that are not historical facts, are "forward-looking” statements (as defined in the Private Securities Litigation Reform Act of 1995). Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, those factors discussed in the section entitled "Risk Factors” in the Company's Quarterly Report on Form 10-Q filed with the SEC on August 7, 2009. You should not place undue reliance on the forward-looking statements in this press release, and the Company disavows any obligation to update or supplement those statements in the event of any changes in the facts, circumstances, or expectations that underlie those statements.

©2009 ZOLL Medical Corporation. All rights reserved. 269 Mill Road, Chelmsford, MA 01824-4105. ZOLL, AutoPulse, AED Plus, AED Pro, CodeNet, E Series, Life Band, M Series, PocketCPR, R Series, Real CPR Help, and See-Thru CPR are registered trademarks of ZOLL Medical Corporation. IVTM and SurePower are trademarks of ZOLL Medical Corporation. All product names are the property of their respective owners.